485
Participants
Start Date
November 30, 2005
Primary Completion Date
October 31, 2009
Study Completion Date
December 31, 2010
Cytarabine or Supportive Care
Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
Dacogen (decitabine) only
20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
St Leonards
East Melbourne
Parkville
South Brisbane
Gyula
Perth
Győr
Taipei
Valhalla
Belgrade
Pittsburgh
Novi Sad
Durham
Madrid
Charleston
Pamplona
Orange Park
Gainesville
Lakeland
Fort Myers
Knoxville
Nantes
Canton
Cincinnati
Terre Haute
Grosse Pointe Woods
Kalamazoo
Sioux City
Glendale
Sioux Falls
Lille
Chicago
Brno
Wichita
Lyon
Tainan City
Houston
Galveston
Austin
Bobigny
Cluj-Napoca
Târgu Mureş
Los Angeles
Hollywood
Miami
Highland Park
Baton Rouge
Shreveport
Boston
Neptune City
New York
Greenville
Nashville
Temple
Eau Claire
Milwaukee
Darlinghurst
Adelaide
Rijeka
Zagreb
Zalaegerszeg
České Budějovice
Pilsen
Créteil
Limoges
Pessac
Budapest
Szeged
Szombathely
Mexico City
Gdansk
Krakow
Poznan
Warsaw
Bucharest
Arkhangelsk
Astrakhan
Barnaul
Izhevsk
Kirov
Kransnodar
Moscow
Novosibirsk
Petrozavodsk
Ryazan
Saint Petersburg
Samara
Saratov
Tyumen
Volgograd
Niš
Girona
Salamanca
Valencia
Changhua
Kaohsiung City
Sutton
Springfield
St. John's
Halifax
Toronto
Prague
Lodz
Lublin
Wroclaw
Badalona-Barcelona
Barcelona
Palma de Mallorca
Eisai Inc.
INDUSTRY